In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £140.00. The company’s shares closed yesterday at ...

TD Cowen analyst Steve Scala maintained a Buy rating on AstraZeneca (AZN – Research Report) today. The company’s shares closed yesterday at $66.64. Discover outperforming stocks and invest ...

AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be getting a huge bargain. When investing, your capital is at risk. The value ...

Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo for the treatment of ...

U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country ...

LONDON, Dec 24 (Reuters) - AstraZeneca (AZN.L), opens new tab has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its experimental precision ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Los Angeles sports organizations are uniting to launch an “LA Strong” custom logo and apparel line that will raise money for ...

The detention of several AstraZeneca employees and eventually the company’s China president Leon Wang unsettled investors, fueling fears of a crackdown similar to the GSK scandal 10 years ago.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of AstraZeneca PLC (NASDAQ ...